{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:20:47Z","timestamp":1787656847808,"version":"build-2736575974"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:00:00Z","timestamp":1759536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:00:00Z","timestamp":1759536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100015359","name":"Connecticut Institute for the Brain and Cognitive Sciences","doi-asserted-by":"publisher","award":["Connecticut Institute for the Brain and Cognitive Sciences"],"award-info":[{"award-number":["Connecticut Institute for the Brain and Cognitive Sciences"]}],"id":[{"id":"10.13039\/100015359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00213-025-06924-6","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T05:51:47Z","timestamp":1759557107000},"page":"1833-1844","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The effects of low-dose ketamine and (2R,6R)-Hydroxynorketamine on affective behaviors associated with protracted oxycodone withdrawal"],"prefix":"10.1007","volume":"243","author":[{"given":"Michael J.","family":"Lehane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2228-1830","authenticated-orcid":false,"given":"Gregory C.","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,4]]},"reference":[{"issue":"4","key":"6924_CR1","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1503\/jpn.160175","volume":"42","author":"LR Aleksandrova","year":"2017","unstructured":"Aleksandrova LR, Phillips AG, Wang YT (2017) Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism. J Psychiatry Neuroscience: JPN 42(4):222\u2013229. https:\/\/doi.org\/10.1503\/jpn.160175","journal-title":"J Psychiatry Neuroscience: JPN"},{"issue":"7","key":"6924_CR2","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/s41386-020-00927-x","volume":"46","author":"JAJ Becker","year":"2021","unstructured":"Becker JAJ, Pellissier LP, Corde Y, Laboute T, L\u00e9aut\u00e9 A, Gand\u00eda J, Le Merrer J (2021) Facilitating mGluR4 activity reverses the long-term deleterious consequences of chronic morphine exposure in male mice. Neuropsychopharmacology 46(7):1373\u20131385. https:\/\/doi.org\/10.1038\/s41386-020-00927-x","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"6924_CR3","doi-asserted-by":"publisher","first-page":"4144","DOI":"10.1038\/s41380-022-01673-w","volume":"27","author":"J Bonaventura","year":"2022","unstructured":"Bonaventura J, Gomez JL, Carlton ML, Lam S, Sanchez-Soto M, Morris PJ, Moaddel R, Kang HJ, Zanos P, Gould TD, Thomas CJ, Sibley DR, Zarate CA, Michaelides M (2022) Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search. Mol Psychiatry 27(10):4144\u20134156. https:\/\/doi.org\/10.1038\/s41380-022-01673-w","journal-title":"Mol Psychiatry"},{"issue":"3","key":"6924_CR4","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/ejn.14580","volume":"51","author":"IM Bravo","year":"2020","unstructured":"Bravo IM, Luster BR, Flanigan ME, Perez PJ, Cogan ES, Schmidt KT, McElligott ZA (2020) Divergent behavioral responses in protracted opioid withdrawal in male and female C57BL\/6J mice. Eur J Neurosci 51(3):742\u2013754. https:\/\/doi.org\/10.1111\/ejn.14580","journal-title":"Eur J Neurosci"},{"key":"6924_CR5","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/7620860","volume":"2016","author":"H Chalana","year":"2016","unstructured":"Chalana H, Kundal T, Gupta V, Malhari AS (2016) Predictors of relapse after inpatient opioid detoxification during 1-year follow-up. J Addict 2016:7620860. https:\/\/doi.org\/10.1155\/2016\/7620860","journal-title":"J Addict"},{"key":"6924_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2023.106279","volume":"186","author":"Y Chen","year":"2023","unstructured":"Chen Y, Yan P, Wei S, Zhu Y, Lai J, Zhou Q (2023) Ketamine metabolite alleviates morphine withdrawal-induced anxiety via modulating nucleus accumbens parvalbumin neurons in male mice. Neurobiol Dis 186:106279. https:\/\/doi.org\/10.1016\/j.nbd.2023.106279","journal-title":"Neurobiol Dis"},{"issue":"10","key":"6924_CR7","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/da.22490","volume":"33","author":"MG Craske","year":"2016","unstructured":"Craske MG, Meuret AE, Ritz T, Treanor M, Dour HJ (2016) Treatment for anhedonia: a neuroscience driven approach. Depress Anxiety 33(10):927\u2013938. https:\/\/doi.org\/10.1002\/da.22490","journal-title":"Depress Anxiety"},{"issue":"1","key":"6924_CR8","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/mp.2016.39","volume":"22","author":"E Dakwar","year":"2017","unstructured":"Dakwar E, Hart CL, Levin FR, Nunes EV, Foltin RW (2017) Cocaine self-administration disrupted by the N-methyl-D-aspartate receptor antagonist ketamine: a randomized, crossover trial. Mol Psychiatry 22(1):76\u201381. https:\/\/doi.org\/10.1038\/mp.2016.39","journal-title":"Mol Psychiatry"},{"key":"6924_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.110987","volume":"253","author":"CR Drinkuth","year":"2023","unstructured":"Drinkuth CR, Lehane MJ, Sartor GC (2023) The effects of (2R,6R)-hydroxynorketamine on oxycodone withdrawal and reinstatement. Drug Alcohol Depend 253:110987. https:\/\/doi.org\/10.1016\/j.drugalcdep.2023.110987","journal-title":"Drug Alcohol Depend"},{"key":"6924_CR10","unstructured":"Dydyk AM, Jain NK, Gupta M (2025) Opioid Use Disorder: Evaluation and Management"},{"key":"6924_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejphar.2016.07.006","volume":"789","author":"RM Enga","year":"2016","unstructured":"Enga RM, Jackson A, Damaj MI, Beardsley PM (2016) Oxycodone physical dependence and its oral self-administration in C57BL\/6J mice. Eur J Pharmacol 789:75\u201380. https:\/\/doi.org\/10.1016\/j.ejphar.2016.07.006","journal-title":"Eur J Pharmacol"},{"key":"6924_CR12","doi-asserted-by":"publisher","DOI":"10.1101\/2024.07.29.605610","author":"MV Foga\u00e7a","year":"2024","unstructured":"Foga\u00e7a MV, Daher F, Picciotto MR (2024) Effects of ketamine on GABAergic and glutamatergic activity in the mPFC: biphasic recruitment of GABA function in antidepressant-like responses. BioRxiv: Preprint Serv Biology. https:\/\/doi.org\/10.1101\/2024.07.29.605610","journal-title":"BioRxiv: Preprint Serv Biology"},{"issue":"3","key":"6924_CR13","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1172\/JCI130808","volume":"130","author":"DM Gerhard","year":"2020","unstructured":"Gerhard DM, Pothula S, Liu R-J, Wu M, Li X-Y, Girgenti MJ, Taylor SR, Duman CH, Delpire E, Picciotto M, Wohleb ES, Duman RS (2020) GABA interneurons are the cellular trigger for ketamine\u2019s rapid antidepressant actions. J Clin Invest 130(3):1336\u20131349. https:\/\/doi.org\/10.1172\/JCI130808","journal-title":"J Clin Invest"},{"issue":"3","key":"6924_CR14","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.biopsych.2010.08.021","volume":"69","author":"C Goeldner","year":"2011","unstructured":"Goeldner C, Lutz P-E, Darcq E, Halter T, Clesse D, Ouagazzal A-M, Kieffer BL (2011) Impaired emotional-like behavior and serotonergic function during protracted abstinence from chronic morphine. Biol Psychiatry 69(3):236\u2013244. https:\/\/doi.org\/10.1016\/j.biopsych.2010.08.021","journal-title":"Biol Psychiatry"},{"issue":"5","key":"6924_CR15","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1124\/molpharm.124.000947","volume":"106","author":"I Gomes","year":"2024","unstructured":"Gomes I, Gupta A, Margolis EB, Fricker LD, Devi LA (2024) Ketamine and major ketamine metabolites function as allosteric modulators of opioid receptors. Mol Pharmacol 106(5):240\u2013252. https:\/\/doi.org\/10.1124\/molpharm.124.000947","journal-title":"Mol Pharmacol"},{"key":"6924_CR16","doi-asserted-by":"publisher","unstructured":"Granza AE, Amaral IM, Monteiro DG, Salti A, Hofer A, Rawas E, R (2023) Social interaction is less rewarding in adult female than in male mice. Brain Sci 13(10). https:\/\/doi.org\/10.3390\/brainsci13101445","DOI":"10.3390\/brainsci13101445"},{"issue":"4","key":"6924_CR17","doi-asserted-by":"publisher","first-page":"e0301848","DOI":"10.1371\/journal.pone.0301848","volume":"19","author":"TM Hillhouse","year":"2024","unstructured":"Hillhouse TM, Partridge KJ, Garrett PI, Honeycutt SC, Porter JH (2024) Effects of (2R,6R)-hydroxynorketamine in assays of acute pain-stimulated and pain-depressed behaviors in mice. PLoS ONE 19(4):e0301848. https:\/\/doi.org\/10.1371\/journal.pone.0301848","journal-title":"PLoS ONE"},{"key":"6924_CR18","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.neuropharm.2018.01.017","volume":"142","author":"I Ivan Ezquerra-Romano","year":"2018","unstructured":"Ivan Ezquerra-Romano I, Lawn W, Krupitsky E, Morgan CJA (2018) Ketamine for the treatment of addiction: evidence and potential mechanisms. Neuropharmacology 142:72\u201382. https:\/\/doi.org\/10.1016\/j.neuropharm.2018.01.017","journal-title":"Neuropharmacology"},{"issue":"11","key":"6924_CR19","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1007\/s11064-004-6884-y","volume":"29","author":"D Ji","year":"2004","unstructured":"Ji D, Sui Z-Y, Ma Y-Y, Luo F, Cui C-L, Han J-S (2004) NMDA receptor in nucleus accumbens is implicated in morphine withdrawal in rats. Neurochem Res 29(11):2113\u20132120. https:\/\/doi.org\/10.1007\/s11064-004-6884-y","journal-title":"Neurochem Res"},{"issue":"6","key":"6924_CR20","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1177\/2167702619855659","volume":"7","author":"BD Kiluk","year":"2019","unstructured":"Kiluk BD, Yip SW, DeVito EE, Carroll KM, Sofuoglu M (2019) Anhedonia as a key clinical feature in the maintenance and treatment of opioid use disorder. Clin Psychol Science: J Association Psychol Sci 7(6):1190\u20131206. https:\/\/doi.org\/10.1177\/2167702619855659","journal-title":"Clin Psychol Science: J Association Psychol Sci"},{"issue":"1","key":"6924_CR21","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.bbr.2011.05.035","volume":"224","author":"H Koike","year":"2011","unstructured":"Koike H, Iijima M, Chaki S (2011) Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res 224(1):107\u2013111. https:\/\/doi.org\/10.1016\/j.bbr.2011.05.035","journal-title":"Behav Brain Res"},{"key":"6924_CR22","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.bbr.2014.05.065","volume":"271","author":"H Koike","year":"2014","unstructured":"Koike H, Chaki S (2014) Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats. Behav Brain Res 271:111\u20135. https:\/\/doi.org\/10.1016\/j.bbr.2014.05.065","journal-title":"Behav Brain Res"},{"key":"6924_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.177604","volume":"999","author":"I Koutrouli","year":"2025","unstructured":"Koutrouli I, Mazochov\u00e1 K, Horsley RR (2025) The antidepressant potential of (2R,6R)-hydroxynorketamine: a detailed review of pre-clinical findings. Eur J Pharmacol 999:177604. https:\/\/doi.org\/10.1016\/j.ejphar.2025.177604","journal-title":"Eur J Pharmacol"},{"issue":"5994","key":"6924_CR24","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1126\/science.1190287","volume":"329","author":"N Li","year":"2010","unstructured":"Li N, Lee B, Liu R-J, Banasr M, Dwyer JM, Iwata M, Li X-Y, Aghajanian G, Duman RS (2010) Mtor-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Sci (New York N Y) 329(5994):959\u2013964. https:\/\/doi.org\/10.1126\/science.1190287","journal-title":"Sci (New York N Y)"},{"key":"6924_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ynstr.2022.100503","volume":"21","author":"Y Li","year":"2022","unstructured":"Li Y, Du Y, Wang C, Lu G, Sun H, Kong Y, Wang W, Lian B, Li C, Wang L, Zhang X, Sun L (2022) (2R,6R)-hydroxynorketamine acts through GluA1-induced synaptic plasticity to alleviate PTSD-like effects in rat models. Neurobiol Stress 21:100503. https:\/\/doi.org\/10.1016\/j.ynstr.2022.100503","journal-title":"Neurobiol Stress"},{"issue":"Pt 1","key":"6924_CR26","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.brainresbull.2016.05.016","volume":"126","author":"Y Liu","year":"2016","unstructured":"Liu Y, Lin D, Wu B, Zhou W (2016) Ketamine abuse potential and use disorder. Brain Res Bull 126(Pt 1):68\u201373. https:\/\/doi.org\/10.1016\/j.brainresbull.2016.05.016","journal-title":"Brain Res Bull"},{"issue":"11","key":"6924_CR27","doi-asserted-by":"publisher","first-page":"5160","DOI":"10.1073\/pnas.1816071116","volume":"116","author":"EW Lumsden","year":"2019","unstructured":"Lumsden EW, Troppoli TA, Myers SJ, Zanos P, Aracava Y, Kehr J, Lovett J, Kim S, Wang F-H, Schmidt S, Jenne CE, Yuan P, Morris PJ, Thomas CJ, Zarate CA, Moaddel R, Traynelis SF, Pereira EFR, Thompson SM, Gould TD (2019) Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function. Proc Natl Acad Sci USA 116(11):5160\u20135169. https:\/\/doi.org\/10.1073\/pnas.1816071116","journal-title":"Proc Natl Acad Sci USA"},{"key":"6924_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.pneurobio.2015.12.001","volume":"152","author":"R Machado-Vieira","year":"2017","unstructured":"Machado-Vieira R, Henter ID, Zarate CA Jr (2017) New targets for rapid antidepressant action. Prog Neurobiol 152:21\u201337. https:\/\/doi.org\/10.1016\/j.pneurobio.2015.12.001","journal-title":"Prog Neurobiol"},{"issue":"4","key":"6924_CR29","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.biopsych.2007.05.028","volume":"63","author":"S Maeng","year":"2008","unstructured":"Maeng S, Zarate CA, Du J, Schloesser RJ, McCammon J, Chen G, Manji HK (2008) Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 63(4):349\u2013352. https:\/\/doi.org\/10.1016\/j.biopsych.2007.05.028","journal-title":"Biol Psychiatry"},{"key":"6924_CR30","doi-asserted-by":"publisher","DOI":"10.1177\/2045125320916657","volume":"10","author":"D Matveychuk","year":"2020","unstructured":"Matveychuk D, Thomas RK, Swainson J, Khullar A, MacKay M-A, Baker GB, Dursun SM (2020) Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers. Ther Adv Psychopharmacol 10:2045125320916657. https:\/\/doi.org\/10.1177\/2045125320916657","journal-title":"Ther Adv Psychopharmacol"},{"key":"6924_CR31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3389\/fnbeh.2020.00075","volume":"14","author":"G McKendrick","year":"2020","unstructured":"McKendrick G, Garrett H, Jones HE, McDevitt DS, Sharma S, Silberman Y, Graziane NM (2020) Ketamine blocks morphine-induced conditioned place preference and anxiety-like behaviors in mice. Front Behav Neurosci 14:75. https:\/\/doi.org\/10.3389\/fnbeh.2020.00075","journal-title":"Front Behav Neurosci"},{"key":"6924_CR32","doi-asserted-by":"publisher","unstructured":"Michael A, Onisiforou A, Georgiou P, Koumas M, Mammadov E, Zanos P (2023) (2R,6R)-hydroxynorketamine facilitates extinction and prevents emotional impairment and stress-induced reinstatement in morphine abstinent mice. https:\/\/doi.org\/10.1101\/2023.12.07.570550","DOI":"10.1101\/2023.12.07.570550"},{"issue":"15","key":"6924_CR33","doi-asserted-by":"publisher","first-page":"3428","DOI":"10.1111\/bph.70018","volume":"182","author":"A Michael","year":"2025","unstructured":"Michael A, Onisiforou A, Georgiou P, Koumas M, Powels C, Mammadov E, Georgiou AN, Zanos P (2025) (2r,6r)-hydroxynorketamine prevents opioid abstinence-related negative affect and stress-induced reinstatement in mice. Br J Pharmacol 182(15):3428\u20133451. https:\/\/doi.org\/10.1111\/bph.70018","journal-title":"Br J Pharmacol"},{"issue":"1\u20133","key":"6924_CR34","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejphar.2012.11.023","volume":"698","author":"R Moaddel","year":"2013","unstructured":"Moaddel R, Abdrakhmanova G, Kozak J, Jozwiak K, Toll L, Jimenez L, Rosenberg A, Tran T, Xiao Y, Zarate CA, Wainer IW (2013) Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in \u03b17 nicotinic acetylcholine receptors. Eur J Pharmacol 698(1\u20133):228\u2013234. https:\/\/doi.org\/10.1016\/j.ejphar.2012.11.023","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"6924_CR35","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0022-3565(25)31050-5","volume":"203","author":"JE Moreton","year":"1977","unstructured":"Moreton JE, Meisch RA, Stark L, Thompson T (1977) Ketamine self-administration by the rhesus monkey. J Pharmacol Exp Ther 203(2):303\u2013309","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"6924_CR36","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.biopsych.2024.09.008","volume":"97","author":"A Onisiforou","year":"2025","unstructured":"Onisiforou A, Michael A, Apostolakis M, Mammadov E, Mitka A, Kalatta MA, Koumas M, Georgiou A, Chatzittofis A, Panayiotou G, Georgiou P, Zarate CA, Zanos P (2025) Ketamine and hydroxynorketamine as novel pharmacotherapies for the treatment of opioid use disorders. Biol Psychiatry 97(6):563\u2013579. https:\/\/doi.org\/10.1016\/j.biopsych.2024.09.008","journal-title":"Biol Psychiatry"},{"issue":"1","key":"6924_CR37","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/ALN.0000000000000285","volume":"121","author":"RK Paul","year":"2014","unstructured":"Paul RK, Singh NS, Khadeer M, Moaddel R, Sanghvi M, Green CE, O\u2019Loughlin K, Torjman MC, Bernier M, Wainer IW (2014) (R,S)-ketamine metabolites (R,S)-norketamine and (2S,6S)-hydroxynorketamine increase the mammalian target of Rapamycin function. Anesthesiology 121(1):149\u2013159. https:\/\/doi.org\/10.1097\/ALN.0000000000000285","journal-title":"Anesthesiology"},{"issue":"1","key":"6924_CR38","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1016\/j.biopsych.2017.10.020","volume":"84","author":"TH Pham","year":"2018","unstructured":"Pham TH, Defaix C, Xu X, Deng S-X, Fabresse N, Alvarez J-C, Landry DW, Brachman RA, Denny CA, Gardier AM (2018) Common neurotransmission recruited in (R,S)-ketamine and (2R,6R)-hydroxynorketamine-induced sustained antidepressant-like effects. Biol Psychiatry 84(1):e3\u2013e6. https:\/\/doi.org\/10.1016\/j.biopsych.2017.10.020","journal-title":"Biol Psychiatry"},{"issue":"24","key":"6924_CR39","doi-asserted-by":"publisher","first-page":"4125","DOI":"10.1016\/j.neuron.2022.09.024","volume":"110","author":"MB Pomrenze","year":"2022","unstructured":"Pomrenze MB, Pinto C, Neumann DF, Llorach PA, Tucciarone P, Morishita JM, Eshel W, Heifets N, B. D., Malenka RC (2022) Modulation of 5-HT release by dynorphin mediates social deficits during opioid withdrawal. Neuron 110(24):4125\u20134143e6. https:\/\/doi.org\/10.1016\/j.neuron.2022.09.024","journal-title":"Neuron"},{"issue":"5","key":"6924_CR40","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/cpt.3391","volume":"116","author":"SM Raja","year":"2024","unstructured":"Raja SM, Guptill JT, Mack M, Peterson M, Byard S, Twieg R, Jordan L, Rich N, Castledine R, Bourne S, Wilmshurst M, Oxendine S, Avula SGC, Zuleta H, Quigley P, Lawson S, McQuaker SJ, Ahmadkhaniha R, Appelbaum LG, Thomas CJ (2024) A phase 1 assessment of the safety, tolerability, pharmacokinetics and pharmacodynamics of (2R,6R)-hydroxynorketamine in healthy volunteers. Clin Pharmacol Ther 116(5):1314\u20131324. https:\/\/doi.org\/10.1002\/cpt.3391","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"6924_CR41","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41386-019-0443-3","volume":"45","author":"LM Riggs","year":"2020","unstructured":"Riggs LM, Aracava Y, Zanos P, Fischell J, Albuquerque EX, Pereira EFR, Thompson SM, Gould TD (2020) (2r,6r)-hydroxynorketamine rapidly potentiates hippocampal glutamatergic transmission through a synapse-specific presynaptic mechanism. Neuropsychopharmacology 45(2):426\u2013436. https:\/\/doi.org\/10.1038\/s41386-019-0443-3","journal-title":"Neuropsychopharmacology"},{"issue":"21","key":"6924_CR42","doi-asserted-by":"publisher","first-page":"5748","DOI":"10.1523\/JNEUROSCI.2875-12.2016","volume":"36","author":"SE Russell","year":"2016","unstructured":"Russell SE, Puttick DJ, Sawyer AM, Potter DN, Mague S, Carlezon WA, Chartoff EH (2016) Nucleus accumbens AMPA receptors are necessary for morphine-withdrawal-induced negative-affective states in rats. J Neuroscience: Official J Soc Neurosci 36(21):5748\u20135762. https:\/\/doi.org\/10.1523\/JNEUROSCI.2875-12.2016","journal-title":"J Neuroscience: Official J Soc Neurosci"},{"key":"6924_CR43","doi-asserted-by":"publisher","first-page":"109308","DOI":"10.1016\/j.neuropharm.2022.109308","volume":"222","author":"A Suzuki","year":"2023","unstructured":"Suzuki A, Hara H, Kimura H (2023) Role of the AMPA receptor in antidepressant effects of ketamine and potential of AMPA receptor potentiators as a novel antidepressant. Neuropharmacology 222:109308. https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109308","journal-title":"Neuropharmacology"},{"issue":"1","key":"6924_CR44","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41386-022-01422-1","volume":"48","author":"SM Thompson","year":"2023","unstructured":"Thompson SM (2023) Plasticity of synapses and reward circuit function in the genesis and treatment of depression. Neuropsychopharmacology: Official Publication Am Coll Neuropsychopharmacol 48(1):90\u2013103. https:\/\/doi.org\/10.1038\/s41386-022-01422-1","journal-title":"Neuropsychopharmacology: Official Publication Am Coll Neuropsychopharmacol"},{"issue":"1","key":"6924_CR45","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1521-0391.2011.00186.x","volume":"21","author":"J Tkacz","year":"2012","unstructured":"Tkacz J, Severt J, Cacciola J, Ruetsch C (2012) Compliance with buprenorphine medication-assisted treatment and relapse to opioid use. Am J Addict 21(1):55\u201362. https:\/\/doi.org\/10.1111\/j.1521-0391.2011.00186.x","journal-title":"Am J Addict"},{"issue":"4","key":"6924_CR46","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1080\/15504263.2021.1979349","volume":"17","author":"KN Tormohlen","year":"2021","unstructured":"Tormohlen KN, Mojtabai R, Seiwell A, McGinty EE, Stuart EA, Tobin KE, Troiani V (2021) Co-occurring opioid use and depressive disorders: patient characteristics and co-occurring health conditions. J Dual Diagnosis 17(4):296\u2013303. https:\/\/doi.org\/10.1080\/15504263.2021.1979349","journal-title":"J Dual Diagnosis"},{"issue":"5","key":"6924_CR47","doi-asserted-by":"publisher","first-page":"e15309","DOI":"10.7759\/cureus.15309","volume":"13","author":"T Tumenta","year":"2021","unstructured":"Tumenta T, Ugwendum DF, Chobufo MD, Mungu EB, Kogan I, Olupona T (2021) Prevalence and trends of opioid use in patients with depression in the united States. Cureus 13(5):e15309. https:\/\/doi.org\/10.7759\/cureus.15309","journal-title":"Cureus"},{"issue":"1","key":"6924_CR48","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.bja.2018.03.011","volume":"121","author":"PE Vlisides","year":"2018","unstructured":"Vlisides PE, Bel-Bahar T, Nelson A, Chilton K, Smith E, Janke E, Tarnal V, Picton P, Harris RE, Mashour GA (2018) Subanaesthetic ketamine and altered states of consciousness in humans. Br J Anaesth 121(1):249\u2013259. https:\/\/doi.org\/10.1016\/j.bja.2018.03.011","journal-title":"Br J Anaesth"},{"issue":"9","key":"6924_CR49","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1038\/s41386-018-0102-0","volume":"43","author":"O Vranjkovic","year":"2018","unstructured":"Vranjkovic O, Winkler G, Winder DG (2018) Ketamine administration during a critical period after forced ethanol abstinence inhibits the development of time-dependent affective disturbances. Neuropsychopharmacology: Official Publication Am Coll Neuropsychopharmacol 43(9):1915\u20131923. https:\/\/doi.org\/10.1038\/s41386-018-0102-0","journal-title":"Neuropsychopharmacology: Official Publication Am Coll Neuropsychopharmacol"},{"key":"6924_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2020.172927","volume":"194","author":"JM Witkin","year":"2020","unstructured":"Witkin JM, Kranzler J, Kaniecki K, Popik P, Smith JL, Hashimoto K, Sporn J (2020) R-(-)-ketamine modifies behavioral effects of morphine predicting efficacy as a novel therapy for opioid use disorder1. Pharmacol Biochem Behav 194:172927. https:\/\/doi.org\/10.1016\/j.pbb.2020.172927","journal-title":"Pharmacol Biochem Behav"},{"issue":"3","key":"6924_CR51","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jphs.2024.01.008","volume":"154","author":"A Yamagishi","year":"2024","unstructured":"Yamagishi A, Ikekubo Y, Mishina M, Ikeda K, Ide S (2024) Loss of the sustained antidepressant-like effect of (2R,6R)-hydroxynorketamine in NMDA receptor GluN2D subunit knockout mice. J Pharmacol Sci 154(3):203\u2013208. https:\/\/doi.org\/10.1016\/j.jphs.2024.01.008","journal-title":"J Pharmacol Sci"},{"issue":"9","key":"6924_CR52","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1038\/s41386-018-0084-y","volume":"43","author":"J-I Yamaguchi","year":"2018","unstructured":"Yamaguchi J-I, Toki H, Qu Y, Yang C, Koike H, Hashimoto K, Mizuno-Yasuhira A, Chaki S (2018) (2R,6R)-hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice. Neuropsychopharmacology 43(9):1900\u20131907. https:\/\/doi.org\/10.1038\/s41386-018-0084-y","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"6924_CR53","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1038\/mp.2017.239","volume":"23","author":"N Yao","year":"2018","unstructured":"Yao N, Skiteva O, Zhang X, Svenningsson P, Chergui K (2018) Ketamine and its metabolite (2R,6R)-hydroxynorketamine induce lasting alterations in glutamatergic synaptic plasticity in the mesolimbic circuit. Mol Psychiatry 23(10):2066\u20132077. https:\/\/doi.org\/10.1038\/mp.2017.239","journal-title":"Mol Psychiatry"},{"key":"6924_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109276","volume":"221","author":"JG Yost","year":"2022","unstructured":"Yost JG, Browne CA, Lucki I (2022) (2r,6r)-hydroxynorketamine (HNK) reverses mechanical hypersensitivity in a model of localized inflammatory pain. Neuropharmacology 221:109276. https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109276","journal-title":"Neuropharmacology"},{"key":"6924_CR55","doi-asserted-by":"publisher","first-page":"1183740","DOI":"10.3389\/fpsyt.2023.1183740","volume":"14","author":"R Zafar","year":"2023","unstructured":"Zafar R, Siegel M, Harding R, Barba T, Agnorelli C, Suseelan S, Roseman L, Wall M, Nutt DJ, Erritzoe D (2023) Psychedelic therapy in the treatment of addiction: the past, present and future. Front Psychiatry 14:1183740. https:\/\/doi.org\/10.3389\/fpsyt.2023.1183740","journal-title":"Front Psychiatry"},{"issue":"7604","key":"6924_CR56","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature17998","volume":"533","author":"P Zanos","year":"2016","unstructured":"Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, Alkondon M, Yuan P, Pribut HJ, Singh NS, Dossou KSS, Fang Y, Huang X-P, Mayo CL, Wainer IW, Albuquerque EX, Thompson SM, Thomas CJ, Zarate CA, Gould TD (2016) NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533(7604):481\u2013486. https:\/\/doi.org\/10.1038\/nature17998","journal-title":"Nature"},{"issue":"3","key":"6924_CR57","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.117.015198","volume":"70","author":"P Zanos","year":"2018","unstructured":"Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, Pereira EFR, Albuquerque EX, Thomas CJ, Zarate CA, Gould TD (2018) Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol Rev 70(3):621\u2013660. https:\/\/doi.org\/10.1124\/pr.117.015198","journal-title":"Pharmacol Rev"},{"issue":"13","key":"6924_CR58","doi-asserted-by":"publisher","first-page":"6441","DOI":"10.1073\/pnas.1819540116","volume":"116","author":"P Zanos","year":"2019","unstructured":"Zanos P, Highland JN, Stewart BW, Georgiou P, Jenne CE, Lovett J, Morris PJ, Thomas CJ, Moaddel R, Zarate CA, Gould TD (2019) (2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions. Proc Natl Acad Sci USA 116(13):6441\u20136450. https:\/\/doi.org\/10.1073\/pnas.1819540116","journal-title":"Proc Natl Acad Sci USA"},{"key":"6924_CR59","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.86022","author":"A Zaytseva","year":"2023","unstructured":"Zaytseva A, Bouckova E, Wiles MJ, Wustrau MH, Schmidt IG, Mendez-Vazquez H, Khatri L, Kim S (2023) Ketamine\u2019s rapid antidepressant effects are mediated by Ca2+-permeable AMPA receptors. Elife. https:\/\/doi.org\/10.7554\/eLife.86022","journal-title":"Elife"},{"issue":"3","key":"6924_CR60","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/FBP.0b013e3282fe88a0","volume":"19","author":"H Zhai","year":"2008","unstructured":"Zhai H, Wu P, Chen S, Li F, Liu Y, Lu L (2008) Effects of scopolamine and ketamine on reconsolidation of morphine conditioned place preference in rats. Behav Pharmacol 19(3):211\u2013216. https:\/\/doi.org\/10.1097\/FBP.0b013e3282fe88a0","journal-title":"Behav Pharmacol"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-025-06924-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-025-06924-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-025-06924-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:40:10Z","timestamp":1787654410000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-025-06924-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,4]]},"references-count":60,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["6924"],"URL":"https:\/\/doi.org\/10.1007\/s00213-025-06924-6","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,4]]},"assertion":[{"value":"28 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Animal experiments were approved by the University of Connecticut Institutional Animal Care and Use Committee (23008).","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Both authors have reviewed the manuscript and consent to publish.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}